DISRUPTING EARLY CANCER DETECTION & MONITORING
MONITORING MALIGNANCIES
THROUGH A SIMPLE BLOOD TEST
​
Non-invasive, Simple Blood Test
​
Applicable to various Malignancies
Affordable
& Rapid
Utilizing Standard Lab Equipment
(No Gene Sequencing or Methylation Test required)
FGL2
DISCOVER THE POWER OF FIBRINOGEN-LIKE PROTEIN (FGL2) BIOMARKER REVOLUTIONIZING CANCER MONITORING
FGL2, a serine protease, demonstrates up-regulation in a multitude of malignancies including Lymphoma, Prostate, Colon and Gastric solid tumors, yet completely absent from surrounding normal tissues.
​
Based on our pioneering discovery of heightened FGL2 expression within peripheral blood cells among patients with malignancies, we developed our proprietary non-invasive assay, designed for the detection and monitoring of malignancies.
MULTIPLE MALIGNANCIES MONITORING
Our innovative assay has been validated across various malignancies including:
​
-
Aggressive Non-Hodgkin's Lymphoma
-
Colorectal Cancer
-
Prostate Cancer
-
Cutaneous T-Cell Lymphoma (Mycosis Fungoides - MF)
For non-invasive differentiation of early-stage MF from inflammatory dermatoses.
​
Strategic Validation Pipeline:​
​
-
Pancreatic Cancer - Early detection
-
Pancreatic Cancer - Treatment response monitoring
-
Metastatic Colorectal Cancer -Treatment response monitoring
​
​
ADVANCED CANCER SCREENING & EARLY DETECTION
​​
Our assay has the potential to serve as a comprehensive screening, detection, and monitoring solution for multiple malignancies, representing a transformative paradigm shift with the capacity to revolutionize cancer care.
​
Our development roadmap extends this biomarker test to address critical malignancies that currently lack effective early detection methods or require costly, time-consuming gene sequencing, with the aim of positioning our test as the new standard for malignancy screening and monitoring, offering a more accessible and efficient alternative to existing methods.
